SONN

SONN - Sonnet BioTherapeutics Holdings Inc Stock Price, Fair Value and News

$1.26 
Market Closed as of 02 Dec 2025, 04:00 pm ET

SONN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SONN Price Action

SONN RSI Chart

SONN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SONN Valuation

SONN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SONN Fundamentals

SONN Revenue

SONN Earnings

SONN Profitability

SONN Investor Care

Revenue & Growth

How Sonnet BioTherapeutics Holdings Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025--1.0M-
2024--550.0K775.0K
2023198.5K173.3K100.0K325.0K
202211.4M5.9M349.9K257.4K
2021--22.5M16.9M
202028.0M---
201928.6M28.9M28.4M30.1M
201841.6M41.2M40.6M30.7M
201741.6M41.4M41.1M41.4M
201637.9M40.2M41.9M41.8M
201534.5M33.8M33.8M36.4M
201411.9M19.6M27.3M31.2M
20137.1M7.1M6.9M8.2M
20122.9M4.4M5.9M6.9M
2011549.3K539.2K1.0M1.5M
2010-447.4K291.9K136.3K
2009---603.0K
SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEsonnetbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12